Paxlovid ni imiti yiperereza ikoreshwa mu kuvura COVID-19 yoroheje cyangwa yoroheje ku bantu bakuru ndetse n’abana [bafite imyaka 12 nayirenga bafite byibura ibiro 88 (40 kg)] hamwe n’ibisubizo byiza byo gupima virusi ya SARS-CoV-2, kandi abafite ibyago byinshi byo gutera imbere kuri COVID-19 ikabije, harimo ibitaro cyangwa urupfu. Paxlovid niperereza kuko iracyigwa. Hano hari amakuru make yerekeye umutekano nuburyo bwiza bwo gukoresha Paxlovid mu kuvura abantu bafite COVID-19 yoroheje.
FDA yemereye gukoresha byihutirwa Paxlovid mu kuvura COVID-19 yoroheje cyangwa yoroheje ku bantu bakuru ndetse n'abana [bafite imyaka 12 n'abayirengeje bapima nibura ibiro 88 (40 kg)] hamwe n'ikizamini cyiza cya virusi ko itera COVID-19, kandi bafite ibyago byinshi byo gutera imbere kuri COVID-19 ikabije, harimo ibitaro cyangwa urupfu, munsi ya EUA.

Paxlovid ntabwo ari imiti yemewe na FDA muri Amerika. Vugana nubuvuzi bwawe kubyerekeye amahitamo yawe cyangwa niba ufite ikibazo. Nuguhitamo gufata Paxlovid.

Paxlovid irimo imiti ibiri: nirmatrelvir na ritonavir.

Nirmatrelvir [PF-07321332] ni SARS-CoV-2 nyamukuru ya protease (Mpro) inhibitor (izwi kandi nka SARS-CoV2 3CL protease inhibitor) ikora mukubuza kwandura virusi mugihe cyambere cyindwara kugirango birinde gutera imbere kwa COVID- 19.

Ritonavir ifatanya na nirmatrelvir kugirango ifashe gutinda metabolisme yayo kugirango ikomeze gukora mumubiri igihe kinini murwego rwo hejuru kugirango ifashe kurwanya virusi.